- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01137799
The Effect of JNJ-39393406 on Event Related Potentials in Stable Schizophrenic Patients
November 7, 2012 updated by: Janssen Pharmaceutica N.V., Belgium
A Double-Blind, Placebo-Controlled, Randomized, Four-Way Cross-Over Study To Investigate Effect Of Single Oral Doses Of JNJ-39393406 On Event-Related Potentials In Subjects With Stable Schizophrenia
This study in patients with stable schizophrenia will investigate the effect of JNJ-39393406 on Event Related Potentials (Auditory Evoked Potential [AEP] P50, AEP P300 and Mismatch Negativity [MMN]) after single dose administration.
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Detailed Description
This is a double-blind (neither physician nor patient knows the name of the assigned drug), placebo-controlled, randomized (study drug assigned by chance), four-way-crossover trial (participants may receive different interventions sequentially during the trial) in patients with stable schizophrenia.
The four-way-crossover treatment phase will consist of four blinded treatment periods separated by a wash out period (the period allowed for the entire administered drug to be eliminated from the body) of 6 to 14 days.
The study duration for each patient will be approximately 12 weeks.
Each patient enrolled will receive 3 (out of 5) dose levels of JNJ-39393406 and one dose of placebo.
Part A of the study will include smoking patients with schizophrenia and will precede part B which will include non-smoking patients with schizophrenia.
Safety evaluations include adverse event monitoring, vital signs and clinical laboratory tests.
The study drug will be given as a single dose on Day 1 of each treatment period as a kind of liquid formulation with 240 mL non-carbonated water between 7:00 AM and 10:30 AM.
Before dosing patients will be given a standard breakfast.
The proposed dose levels for this study (Part A and Part B) will range from 10 to 200 mg.
Study Type
Interventional
Enrollment (Actual)
47
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Berlin, Germany
-
Erlangen, Germany
-
München, Germany
-
Neuss, Germany
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 55 years (ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- Male between 18 and 55 years of age, inclusive
- A known history of schizophrenia of at least 12 months by the referring psychiatrist
- DSM-IV criteria for Schizophrenia (including all subtypes)
- Stable treatment for at least 3 months (minor changes are acceptable upon confirmation by the sponsor representative)
- Medically stable on the basis of physical examination, medical history, vital signs, and 12-lead ECG performed at screening. If there are abnormalities, they must be consistent with the underlying illness in the study population
- Medically stable on the basis of clinical laboratory tests performed at screening. If the results of the serum chemistry panel, hematology, or urinalysis are outside the normal reference ranges, the subject may be included only if the investigator judges the abnormalities or deviations from normal to be not clinically significant or to be appropriate and reasonable for the population under study. This determination must be recorded in the subject source documents and initialed by the investigator
- BMI between 18 and 35 kg/m² inclusive (BMI = weight/height²)
- For the pharmacogenomic component of this study subjects must have signed a separate written informed consent indicating willingness to participate in Part 1 genetic testing (mandatory), and indicate either consent or refusal for Part 2 DNA storage. Subject participation in the genetic testing component of the study (Part 1) is mandatory. Participation in the DNA storage component (Part 2) is voluntary and refusal to participate will not result in ineligibility for the main part of the study
Exclusion Criteria:
- A DSM-IV axis I diagnosis other than schizophrenia
- Clinically significant abnormal values for clinical chemistry, hematology or urinalysis at screening or admission. It is expected that laboratory values will generally be within the normal range for the laboratory, though minor deviations, which are not considered to be of clinical significance to the investigator, are acceptable. Values of ALT/AST < 2 fold the upper limit of normal will be allowed
- Clinically significant abnormal physical examination, vital signs or 12 lead ECG at screening. Minor deviations in ECG, which are not considered to be of clinical significance to the investigator, are acceptable
- QTcb >470ms
- A DSM-IV diagnosis of substance dependence within 6 months prior to screening evaluation (caffeine dependence is not exclusionary. Patients with a positive drug screen at screening may be included provided use does not lead to a DSM-IV diagnosis of substance dependence and patients consents to abstain from illegal drugs within 3 days prior to Day -1 and at any time during the study)
- Treatment-resistant subjects (failure to respond to two different antipsychotic drugs in the past)
- PANSS scores > 70
- Suicidal risk (assessed by the investigator such as, prior attempts to suicide, command hallucinations and / or hopelessness)
- Use of clozapine within 3 months before screening until follow-up
- Use of more than two antipsychotic drugs within 3 months before dosing until follow up
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: 001
JNJ-39393406 10mg nanosuspension (sort of liquid formulation) once daily (single dose)
|
50mg nanosuspension (sort of liquid formulation) once daily (single dose)
200mg nanosuspension (sort of liquid formulation) once daily (single dose)
100mg nanosuspension (sort of liquid formulation) once daily (single dose)
10mg nanosuspension (sort of liquid formulation) once daily (single dose)
30mg nanosuspension (sort of liquid formulation) once daily (single dose)
|
EXPERIMENTAL: 002
JNJ-39393406 30mg nanosuspension (sort of liquid formulation) once daily (single dose)
|
50mg nanosuspension (sort of liquid formulation) once daily (single dose)
200mg nanosuspension (sort of liquid formulation) once daily (single dose)
100mg nanosuspension (sort of liquid formulation) once daily (single dose)
10mg nanosuspension (sort of liquid formulation) once daily (single dose)
30mg nanosuspension (sort of liquid formulation) once daily (single dose)
|
EXPERIMENTAL: 003
JNJ-39393406 50mg nanosuspension (sort of liquid formulation) once daily (single dose)
|
50mg nanosuspension (sort of liquid formulation) once daily (single dose)
200mg nanosuspension (sort of liquid formulation) once daily (single dose)
100mg nanosuspension (sort of liquid formulation) once daily (single dose)
10mg nanosuspension (sort of liquid formulation) once daily (single dose)
30mg nanosuspension (sort of liquid formulation) once daily (single dose)
|
EXPERIMENTAL: 004
JNJ-39393406 100mg nanosuspension (sort of liquid formulation) once daily (single dose)
|
50mg nanosuspension (sort of liquid formulation) once daily (single dose)
200mg nanosuspension (sort of liquid formulation) once daily (single dose)
100mg nanosuspension (sort of liquid formulation) once daily (single dose)
10mg nanosuspension (sort of liquid formulation) once daily (single dose)
30mg nanosuspension (sort of liquid formulation) once daily (single dose)
|
EXPERIMENTAL: 005
JNJ-39393406 200mg nanosuspension (sort of liquid formulation) once daily (single dose)
|
50mg nanosuspension (sort of liquid formulation) once daily (single dose)
200mg nanosuspension (sort of liquid formulation) once daily (single dose)
100mg nanosuspension (sort of liquid formulation) once daily (single dose)
10mg nanosuspension (sort of liquid formulation) once daily (single dose)
30mg nanosuspension (sort of liquid formulation) once daily (single dose)
|
PLACEBO_COMPARATOR: 006
placebo Once daily (single dose)
|
Once daily (single dose)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Improvement of deficits (i.e. sensory gating deficits) in event related potentials like Auditory Evoked Potentials P50 and P300 and Mismatch Negativity.
Time Frame: Predose and 2 and 5 hours post dose during each treatment period.
|
Predose and 2 and 5 hours post dose during each treatment period.
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Improvement in continuous performance testing
Time Frame: Predose, 2h and 5 post dosing during each treatment period
|
Predose, 2h and 5 post dosing during each treatment period
|
Plasma concentrations of JNJ-39393406 (PK blood samples)
Time Frame: Predose, 1h, 1h45, 3h, 4h45 and 6h postdose during each treatment period
|
Predose, 1h, 1h45, 3h, 4h45 and 6h postdose during each treatment period
|
Number of patients with clinical significant changes in vitals signs
Time Frame: Baseline, predose and 6h post dose during each treatment period and follow up visit.
|
Baseline, predose and 6h post dose during each treatment period and follow up visit.
|
Number of patients with clinical significant changes in ECG parameters
Time Frame: baseline, predose and 6h post dose during each treatment period and follow up
|
baseline, predose and 6h post dose during each treatment period and follow up
|
Number of patients with clinical clinical significant changes in clinical laboratory parameters
Time Frame: baseline, predose and 6h post dose during each treatment period and Follow Up
|
baseline, predose and 6h post dose during each treatment period and Follow Up
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
August 1, 2009
Study Completion (ACTUAL)
March 1, 2011
Study Registration Dates
First Submitted
June 3, 2010
First Submitted That Met QC Criteria
June 3, 2010
First Posted (ESTIMATE)
June 4, 2010
Study Record Updates
Last Update Posted (ESTIMATE)
November 8, 2012
Last Update Submitted That Met QC Criteria
November 7, 2012
Last Verified
November 1, 2012
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CR016762
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Schizophrenia
-
Organon and CoCompletedSchizophrenia, Paranoid | Schizophrenia, Disorganized | Schizophrenia, Undifferentiated
-
Organon and CoCompletedSchizophrenia, Paranoid | Schizophrenia, Disorganized | Schizophrenia, Undifferentiated
-
Bradley LegaRecruiting
-
All India Institute of Medical Sciences, BhubaneswarRecruitingTreatment Resistant SchizophreniaIndia
-
King's College LondonSouth London and Maudsley NHS Foundation TrustRecruitingTreatment-resistant Schizophrenia | Healthy Controls | Treatment-responsive SchizophreniaUnited Kingdom
-
University of Sao PauloUnknownRefractory Schizophrenia | Super Refractory SchizophreniaBrazil
-
Peking UniversityNot yet recruitingTreatment-resistant Schizophrenia
-
Ohio State UniversityRecruitingTreatment-resistant SchizophreniaUnited States
-
University Hospital, BrestRecruitingSchizophrenia | Schizophrenia Prodromal | Schizophrenia, ChildhoodFrance
-
NYU Langone HealthNot yet recruitingTreatment-resistant SchizophreniaUnited States
Clinical Trials on JNJ-39393406
-
Johnson & Johnson Pharmaceutical Research & Development...Completed
-
Johnson & Johnson Pharmaceutical Research & Development...Completed
-
Tangent DataJohnson & Johnson Pharmaceutical Research & Development, L.L.C.CompletedDepressionMoldova, Republic of, Romania
-
Johnson & Johnson Pharmaceutical Research & Development...Completed
-
Chengappa, K.N. Roy, MDNational Institutes of Health (NIH)Completed
-
K.N. Roy ChengappaUniversity of Pittsburgh; National Institutes of Health (NIH); Virginia Commonwealth...Completed
-
Janssen Research & Development, LLCRecruitingLymphoma, Non-HodgkinDenmark, Israel, Spain, Australia
-
Janssen-Cilag International NVCompleted
-
Janssen Research & Development, LLCCompleted
-
Janssen Research & Development, LLCCompleted